|
1
|
Goff BA, Mandel LS, Drescher CW, Urban N,
Gough S, Schurman KM, Patras J, Mahony BS and Andersen MR:
Development of an ovarian cancer symptom index: Possibilities for
earlier detection. Cancer. 109:221–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Borley J, Wilhelm-Benartzi C, Yazbek J,
Williamson R, Bharwani N, Stewart V, Carson I, Hird E, McIndoe A,
Farthing A, et al: Radiological predictors of cytoreductive
outcomes in patients with advanced ovarian cancer. BJOG.
122:843–849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gershenson DM, Sun CC, Lu KH, Coleman RL,
Sood AK, Malpica A, Deavers MT, Silva EG and Bodurka DC: Clinical
behavior of stage II–IV low-grade serous carcinoma of the ovary.
Obstet Gynecol. 108:361–368. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bankhead CR, Kehoe ST and Austoker J:
Symptoms associated with diagnosis of ovarian cancer: A systematic
review. BJOG. 112:857–865. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Borley J, Wilhelm-Benartzi C, Brown R and
Ghaem-Maghami S: Does tumour biology determine surgical success in
the treatment of epithelial ovarian cancer? A systematic literature
review. Br J Cancer. 107:1069–1074. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ohshio Y, Teramoto K, Hanaoka J, Tezuka N,
Itoh Y, Asai T, Daigo Y and Ogasawara K: Cancer-associated
fibroblast-targeted strategy enhances antitumor immune responses in
dendritic cell-based vaccine. Cancer Sci. 106:134–142. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ziani L, Chouaib S and Thiery J:
Alteration of the Antitumor Immune Response by Cancer-Associated
Fibroblasts. Front Immunol. 9:4142018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Willmott LJ and Fruehauf JP: Targeted
therapy in ovarian cancer. J Oncol. 2010:7404722010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun Y: Translational horizons in the tumor
microenvironment: Harnessing breakthroughs and targeting cures. Med
Res Rev. 35:408–436. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cancer Genome Atlas Research Network, .
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ahmed N and Stenvers KL: Getting to know
ovarian cancer ascites: Opportunities for targeted therapy-based
translational research. Front Oncol. 3:2562013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Balkwill FR, Capasso M and Hagemann T: The
tumor microenvironment at a glance. J Cell Sci. 125:5591–5596.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Worzfeld T, Pogge von Strandmann E, Huber
M, Adhikary T, Wagner U, Reinartz S and Müller R: The unique
molecular and cellular microenvironment of ovarian cancer. Front
Oncol. 7:242017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ghoneum A, Afify H, Salih Z, Kelly M and
Said N: Role of tumor microenvironment in ovarian cancer
pathobiology. Oncotarget. 9:22832–22849. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cirri P and Chiarugi P:
Cancer-associated-fibroblasts and tumour cells: A diabolic liaison
driving cancer progression. Cancer Metastasis Rev. 31:195–208.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Trivedi N, Marsh P, Goold RG, Wood-Kaczmar
A and Gordon-Weeks PR: Glycogen synthase kinase-3beta
phosphorylation of MAP1B at Ser1260 and Thr1265 is spatially
restricted to growing axons. J Cell Sci. 118:993–1005. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Slany A, Bileck A, Muqaku B and Gerner C:
Targeting breast cancer-associated fibroblasts to improve
anti-cancer therapy. Breast. 24:532–538. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ghoneum A, Afify H, Salih Z, Kelly M and
Said N: Role of tumor microenvironment in the pathobiology of
ovarian cancer: Insights and therapeutic opportunities. Cancer Med.
7:5047–5056. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Parsonage G, Filer AD, Haworth O, Nash GB,
Rainger GE, Salmon M and Buckley CD: A stromal address code defined
by fibroblasts. Trends Immunol. 26:150–156. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tomasek JJ, McRae J, Owens GK and Haaksma
CJ: Regulation of alpha-smooth muscle actin expression in
granulation tissue myofibroblasts is dependent on the intronic CArG
element and the transforming growth factor-beta1 control element.
Am J Pathol. 166:1343–1351. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rodemann HP and Müller GA:
Characterization of human renal fibroblasts in health and disease:
II. In vitro growth, differentiation, and collagen synthesis of
fibroblasts from kidneys with interstitial fibrosis. Am J Kidney
Dis. 17:684–686. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chang HY, Chi JT, Dudoit S, Bondre C, van
de Rijn M, Botstein D and Brown PO: Diversity, topographic
differentiation, and positional memory in human fibroblasts. Proc
Natl Acad Sci USA. 99:12877–12882. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Simian M, Hirai Y, Navre M, Werb Z,
Lochter A and Bissell MJ: The interplay of matrix
metalloproteinases, morphogens and growth factors is necessary for
branching of mammary epithelial cells. Development. 128:3117–3131.
2001.PubMed/NCBI
|
|
25
|
Tuxhorn JA, Ayala GE, Smith MJ, Smith VC,
Dang TD and Rowley DR: Reactive stroma in human prostate cancer:
Induction of myofibroblast phenotype and extracellular matrix
remodeling. Clin Cancer Res. 8:2912–2923. 2002.PubMed/NCBI
|
|
26
|
Dotto GP, Weinberg RA and Ariza A:
Malignant transformation of mouse primary keratinocytes by Harvey
sarcoma virus and its modulation by surrounding normal cells. Proc
Natl Acad Sci USA. 85:6389–6393. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Castor CW, Wilson SM, Heiss PR and Seidman
JC: Activation of lung connective tissue cells in vitro. Am Rev
Respir Dis. 120:101–106. 1979.PubMed/NCBI
|
|
28
|
Müller GA and Rodemann HP:
Characterization of human renal fibroblasts in health and disease:
I. Immunophenotyping of cultured tubular epithelial cells and
fibroblasts derived from kidneys with histologically proven
interstitial fibrosis. Am J Kidney Dis. 17:680–683. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Calon A, Tauriello DV and Batlle E:
TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer
Biol. 25:15–22. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Marsh T, Pietras K and McAllister SS:
Fibroblasts as architects of cancer pathogenesis. Biochim Biophys
Acta. 1832:1070–1078. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kalluri R and Zeisberg M: Fibroblasts in
cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yáñez-Mó M, Lara-Pezzi E, Selgas R,
Ramírez-Huesca M, Domínguez-Jiménez C, Jiménez-Heffernan JA,
Aguilera A, Sánchez-Tomero JA, Bajo MA, Alvarez V, et al:
Peritoneal dialysis and epithelial-to-mesenchymal transition of
mesothelial cells. N Engl J Med. 348:403–413. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sandoval P, Jiménez-Heffernan JA,
Rynne-Vidal Á, Pérez-Lozano ML, Gilsanz Á, Ruiz-Carpio V, Reyes R,
García-Bordas J, Stamatakis K, Dotor J, et al: Carcinoma-associated
fibroblasts derive from mesothelial cells via
mesothelial-to-mesenchymal transition in peritoneal metastasis. J
Pathol. 231:517–531. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ishii G, Ochiai A and Neri S: Phenotypic
and functional heterogeneity of cancer-associated fibroblast within
the tumor microenvironment. Adv Drug Deliv Rev. 99:186–196. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kalluri R: The biology and function of
fibroblasts in cancer. Nat Rev Cancer. 16:582–598. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Marsh EE, Ekpo GE, Cardozo ER, Brocks M,
Dune T and Cohen LS: Racial differences in fibroid prevalence and
ultrasound findings in asymptomatic young women (18–30 years old):
A pilot study. Fertil Steril. 99:1951–1957. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bainbridge P: Wound healing and the role
of fibroblasts. J Wound Care. 22:407–408, 410-412. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Duffield JS, Lupher M, Thannickal VJ and
Wynn TA: Host responses in tissue repair and fibrosis. Annu Rev
Pathol. 8:241–276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kalluri R: EMT: When epithelial cells
decide to become mesenchymal-like cells. J Clin Invest.
119:1417–1419. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Klingberg F, Hinz B and White ES: The
myofibroblast matrix: Implications for tissue repair and fibrosis.
J Pathol. 229:298–309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zeisberg M and Kalluri R: Cellular
mechanisms of tissue fibrosis. 1. Common and organ-specific
mechanisms associated with tissue fibrosis. Am J Physiol Cell
Physiol. 304:C216–C225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Procopio MG, Laszlo C, Al Labban D, Kim
DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, et
al: Combined CSL and p53 downregulation promotes cancer-associated
fibroblast activation. Nat Cell Biol. 17:1193–1204. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Räsänen K and Vaheri A: Activation of
fibroblasts in cancer stroma. Exp Cell Res. 316:2713–2722. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cai J, Tang H, Xu L, Wang X, Yang C, Ruan
S, Guo J, Hu S and Wang Z: Fibroblasts in omentum activated by
tumor cells promote ovarian cancer growth, adhesion and
invasiveness. Carcinogenesis. 33:20–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Alexander J and Cukierman E: Stromal
dynamic reciprocity in cancer: Intricacies of fibroblastic-ECM
interactions. Curr Opin Cell Biol. 42:80–93. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lau TS, Chan LK, Wong EC, Hui CW, Sneddon
K, Cheung TH, Yim SF, Lee JH, Yeung CS, Chung TK, et al: A loop of
cancer-stroma-cancer interaction promotes peritoneal metastasis of
ovarian cancer via TNFα-TGFα-EGFR. Oncogene. 36:3576–3587. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rynne-Vidal A, Au-Yeung CL,
Jiménez-Heffernan JA, Pérez-Lozano ML, Cremades-Jimeno L, Bárcena
C, Cristóbal-García I, Fernández-Chacón C, Yeung TL, Mok SC, et al:
Mesothelial-to-mesenchymal transition as a possible therapeutic
target in peritoneal metastasis of ovarian cancer. J Pathol.
242:140–151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dirat B, Bochet L, Dabek M, Daviaud D,
Dauvillier S, Majed B, Wang YY, Meulle A, Salles B, Le Gonidec S,
et al: Cancer-associated adipocytes exhibit an activated phenotype
and contribute to breast cancer invasion. Cancer Res. 71:2455–2465.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bochet L, Lehuédé C, Dauvillier S, Wang
YY, Dirat B, Laurent V, Dray C, Guiet R, Maridonneau-Parini I, Le
Gonidec S, et al: Adipocyte-derived fibroblasts promote tumor
progression and contribute to the desmoplastic reaction in breast
cancer. Cancer Res. 73:5657–5668. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zoico E, Darra E, Rizzatti V, Budui S,
Franceschetti G, Mazzali G, Rossi AP, Fantin F, Menegazzi M, Cinti
S, et al: Adipocytes WNT5a mediated dedifferentiation: A possible
target in pancreatic cancer microenvironment. Oncotarget.
7:20223–20235. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lawler HM, Underkofler CM, Kern PA,
Erickson C, Bredbeck B and Rasouli N: Adipose tissue hypoxia,
inflammation, and fibrosis in obese insulin-sensitive and obese
insulin-resistant subjects. J Clin Endocrinol Metab. 101:1422–1428.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Evrard SM, Lecce L, Michelis KC,
Nomura-Kitabayashi A, Pandey G, Purushothaman KR, d'Escamard V, Li
JR, Hadri L, Fujitani K, et al: Endothelial to mesenchymal
transition is common in atherosclerotic lesions and is associated
with plaque instability. Nat Commun. 7:118532016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Madar S, Goldstein I and Rotter V: ‘Cancer
associated fibroblasts’--more than meets the eye. Trends Mol Med.
19:447–453. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yeung TL, Leung CS, Wong KK, Samimi G,
Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ and Mok SC: TGF-β
modulates ovarian cancer invasion by upregulating CAF-derived
versican in the tumor microenvironment. Cancer Res. 73:5016–5028.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang L, Yang D, Tian J, Gao A, Shen Y, Ren
X, Li X, Jiang G and Dong T: Tumor necrosis factor receptor 2/AKT
and ERK signaling pathways contribute to the switch from
fibroblasts to CAFs by progranulin in microenvironment of
colorectal cancer. Oncotarget. 8:26323–26333. 2017.PubMed/NCBI
|
|
56
|
Gomes FG, Nedel F, Alves AM, Nör JE and
Tarquinio SB: Tumor angiogenesis and lymphangiogenesis:
Tumor/endothelial crosstalk and cellular/microenvironmental
signaling mechanisms. Life Sci. 92:101–107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ferrara N: Pathways mediating
VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev.
21:21–26. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang J and Liu J: Tumor stroma as targets
for cancer therapy. Pharmacol Ther. 137:200–215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhao Q, Gui T, Qian Q, Li L and Shen K:
B-cell-specific Moloney murine leukemia virus integration site 1:
Potential stratification factor and therapeutic target for
epithelial ovarian cancer. OncoTargets Ther. 9:5203–5208. 2016.
View Article : Google Scholar
|
|
60
|
Jeter CR, Yang T, Wang J, Chao HP and Tang
DG: Concise Review: NANOG in cancer stem cells and tumor
development: An update and outstanding questions. Stem Cells.
33:2381–2390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Denduluri SK, Idowu O, Wang Z, Liao Z, Yan
Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L, et al: Insulin-like
growth factor (IGF) signaling in tumorigenesis and the development
of cancer drug resistance. Genes Dis. 2:13–25. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Singh RK, Dhadve A, Sakpal A, De A and Ray
P: An active IGF-1R-AKT signaling imparts functional heterogeneity
in ovarian CSC population. Sci Rep. 6:366122016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Albrengues J, Bertero T, Grasset E, Bonan
S, Maiel M, Bourget I, Philippe C, Herraiz Serrano C, Benamar S,
Croce O, et al: Epigenetic switch drives the conversion of
fibroblasts into proinvasive cancer-associated fibroblasts. Nat
Commun. 6:102042015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bechtel W, McGoohan S, Zeisberg EM, Müller
GA, Kalbacher H, Salant DJ, Müller CA, Kalluri R and Zeisberg M:
Methylation determines fibroblast activation and fibrogenesis in
the kidney. Nat Med. 16:544–550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zeisberg EM and Zeisberg M: The role of
promoter hypermethylation in fibroblast activation and
fibrogenesis. J Pathol. 229:264–273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jiang L, Gonda TA, Gamble MV, Salas M,
Seshan V, Tu S, Twaddell WS, Hegyi P, Lazar G, Steele I, et al:
Global hypomethylation of genomic DNA in cancer-associated
myofibroblasts. Cancer Res. 68:9900–9908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Clayton A, Evans RA, Pettit E, Hallett M,
Williams JD and Steadman R: Cellular activation through the
ligation of intercellular adhesion molecule-1. J Cell Sci.
111:443–453. 1998.PubMed/NCBI
|
|
68
|
Bhowmick NA, Neilson EG and Moses HL:
Stromal fibroblasts in cancer initiation and progression. Nature.
432:332–337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mao Y, Keller ET, Garfield DH, Shen K and
Wang J: Stromal cells in tumor microenvironment and breast cancer.
Cancer Metastasis Rev. 32:303–315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zheng X, Turkowski K, Mora J, Brüne B,
Seeger W, Weigert A and Savai R: Redirecting tumor-associated
macrophages to become tumoricidal effectors as a novel strategy for
cancer therapy. Oncotarget. 8:48436–48452. 2017.PubMed/NCBI
|
|
71
|
De Veirman K, Rao L, De Bruyne E, Menu E,
Van Valckenborgh E, Van Riet I, Frassanito MA, Di Marzo L, Vacca A
and Vanderkerken K: Cancer associated fibroblasts and tumor growth:
Focus on multiple myeloma. Cancers (Basel). 6:1363–1381. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Cho H, Seo Y, Loke KM, Kim SW, Oh SM, Kim
JH, Soh J, Kim HS, Lee H, Kim J, et al: Cancer-stimulated CAFs
enhance monocyte differentiation and protumoral TAM activation via
IL6 and GM-CSF secretion. Clin Cancer Res. 24:5407–5421. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
LeBleu VS and Kalluri R: A peek into
cancer-associated fibroblasts: origins, functions and translational
impact. Dis Model Mech. 11:dmm0294472018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hu-Lieskovan S, Mok S, Homet Moreno B,
Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG,
Comin-Anduix B, et al: Improved antitumor activity of immunotherapy
with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl
Med. 7:279ra412015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Hirata E, Girotti MR, Viros A, Hooper S,
Spencer-Dene B, Matsuda M, Larkin J, Marais R and Sahai E:
Intravital imaging reveals how BRAF inhibition generates
drug-tolerant microenvironments with high integrin β1/FAK
signaling. Cancer Cell. 27:574–588. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Nagasaki T, Hara M, Nakanishi H, Takahashi
H, Sato M and Takeyama H: Interleukin-6 released by colon
cancer-associated fibroblasts is critical for tumour angiogenesis:
Anti-interleukin-6 receptor antibody suppressed angiogenesis and
inhibited tumour-stroma interaction. Br J Cancer. 110:469–478.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kato T, Noma K, Ohara T, Kashima H,
Katsura Y, Sato H, Komoto S, Katsube R, Ninomiya T, Tazawa H, et
al: Cancer-associated fibroblasts affect intratumoral
CD8+ and FoxP3+ T cells via IL6 in the tumor
microenvironment. Clin Cancer Res. 24:4820–4833. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Hofmeister V, Schrama D and Becker JC:
Anti-cancer therapies targeting the tumor stroma. Cancer Immunol
Immunother. 57:1–17. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Valero T, Steele S, Neumüller K, Bracher
A, Niederleithner H, Pehamberger H, Petzelbauer P and Loewe R:
Combination of dacarbazine and dimethylfumarate efficiently reduces
melanoma lymph node metastasis. J Invest Dermatol. 130:1087–1094.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Umansky V and Sevko A: Overcoming
immunosuppression in the melanoma microenvironment induced by
chronic inflammation. Cancer Immunol Immunother. 61:275–282. 2012.
View Article : Google Scholar : PubMed/NCBI
|
